Yahoo Finance

Market Cap: £11.73M

Provexis plc, with a market cap of £11.73 million, is pre-revenue and unprofitable, generating only £1 million in revenue from its Vitamins & Nutrition Products segment. The company benefits from being debt-free and having no long-term liabilities. Its seasoned board offers stability with an average tenure of 14 years. Despite having sufficient cash runway for over three years based on current free cash flow trends, Provexis faces challenges such as high share price volatility and a negative return on equity of -136.65%. Additionally, earnings have declined by 5.5% annually over the past five years.

• Get an in-depth perspective on Provexis' performance by reading our balance sheet health report here.

• Assess Provexis' previous results with our detailed historical performance reports.

Castings

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Castings P.L.C. is involved in iron casting and machining operations across various regions including the UK, Europe, and the Americas, with a market cap of £110.82 million.

Operations: The company's revenue is derived from £225.67 million in foundry operations and £35.57 million in machining operations.

Market Cap: £110.82M

Castings P.L.C., with a market cap of £110.82 million, is financially stable, having no debt and sufficient short-term assets (£98.3M) to cover both short-term (£27.8M) and long-term liabilities (£7.9M). The company generates substantial revenue from its foundry (£225.67 million) and machining operations (£35.57 million), although recent earnings growth has been negative (-21.6%). Despite trading at 44.2% below estimated fair value, challenges include a low return on equity (9.5%) and declining earnings forecasts over the next three years by an average of 0.4% annually, alongside an unsustainable dividend yield of 7.22%.

• Take a closer look at Castings' potential here in our financial health report.

• Examine Castings' earnings growth report to understand how analysts expect it to perform.

Turning Ideas Into Actions

• Unlock our comprehensive list of 391 UK Penny Stocks by clicking here.

• Looking For Alternative Opportunities? AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AIM:CMX AIM:PXS and LSE:CGS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com